Your browser doesn't support javascript.
loading
In vivo CRISPR editing with no detectable genome-wide off-target mutations.
Akcakaya, Pinar; Bobbin, Maggie L; Guo, Jimmy A; Malagon-Lopez, Jose; Clement, Kendell; Garcia, Sara P; Fellows, Mick D; Porritt, Michelle J; Firth, Mike A; Carreras, Alba; Baccega, Tania; Seeliger, Frank; Bjursell, Mikael; Tsai, Shengdar Q; Nguyen, Nhu T; Nitsch, Roberto; Mayr, Lorenz M; Pinello, Luca; Bohlooly-Y, Mohammad; Aryee, Martin J; Maresca, Marcello; Joung, J Keith.
Afiliación
  • Akcakaya P; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Bobbin ML; Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
  • Guo JA; Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA, USA.
  • Malagon-Lopez J; Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • Clement K; Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
  • Garcia SP; Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA, USA.
  • Fellows MD; Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
  • Porritt MJ; Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA, USA.
  • Firth MA; Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • Carreras A; Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
  • Baccega T; Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA, USA.
  • Seeliger F; Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • Bjursell M; Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.
  • Tsai SQ; Advanced Medicines Safety, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Nguyen NT; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Nitsch R; Quantitative Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Mayr LM; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Pinello L; Wallenberg Laboratory and Sahlgrenska Center for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Bohlooly-Y M; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Aryee MJ; San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Maresca M; Pathology Science, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Joung JK; Discovery Biology, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Nature ; 561(7723): 416-419, 2018 09.
Article en En | MEDLINE | ID: mdl-30209390

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Especificidad por Sustrato / Genoma / Proteínas Asociadas a CRISPR / Sistemas CRISPR-Cas / Edición Génica / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Nature Año: 2018 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Especificidad por Sustrato / Genoma / Proteínas Asociadas a CRISPR / Sistemas CRISPR-Cas / Edición Génica / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Nature Año: 2018 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido